2016
DOI: 10.1097/moh.0000000000000212
|View full text |Cite
|
Sign up to set email alerts
|

Should autotransplantation in acute myeloid leukemia in first complete remission be revisited?

Abstract: ASCT has been associated with prolonged disease-free survival as compared to chemotherapy, especially in the favorable and intermediate risk groups. Advances in immunotherapy in AML may propel ASCT as a platform for various immunologic maneuvers.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 26 publications
0
5
0
Order By: Relevance
“…Autologous stem cell transplantation in first CR is still advocated by some investigators and included as a therapeutic option in the ELN guidelines 39 . It is suggested that autologous transplantation could benefit to favorable or intermediate-risk AML patients especially those with negative minimal residual disease.…”
Section: Discussionmentioning
confidence: 99%
“…Autologous stem cell transplantation in first CR is still advocated by some investigators and included as a therapeutic option in the ELN guidelines 39 . It is suggested that autologous transplantation could benefit to favorable or intermediate-risk AML patients especially those with negative minimal residual disease.…”
Section: Discussionmentioning
confidence: 99%
“…Overall, the patients autografted in CR1 had superior leukemia-free survival (LFS) and lower leukemia recurrence, but not overall survival (OS) if compared with those treated with intensive chemotherapy. The summary of numerous studies has demonstrated that AHSCT should be offered for younger patients in the favorable and intermediate cytogenetic risk groups, however its optimal role requires further investigations [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…Consequently, they are offered consolidation treatment in CR1 with either conventional chemotherapy, autologous or allogeneic transplantation [2][3][4]. Among these options, high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) can be applied to consolidate CR1 in AML patients who have favorable or intermediate risk cytogenetic and molecular abnormalities [5][6][7][8].…”
Section: Introductionmentioning
confidence: 99%